GC054 Frailty In The Older People
Frailty is a multidimensional syndrome of decreased physiological reserve and increased vulnerability to stressors in older adults, resulting in heightened risk of falls, disability, hospitalization, and mortality.
Frailty and Sarcopenia in Older People
Big Idea: Frailty is a biological syndrome of diminished physiological reserve that makes older adults disproportionately vulnerable to stressors — even minor ones like a urinary tract infection or a medication change can cascade into falls, disability, hospitalisation, and death. Sarcopenia (age-related loss of skeletal muscle mass and strength) is a major biological driver of frailty, and the two conditions overlap heavily in pathophysiology and management. Understanding frailty allows clinicians to risk-stratify patients, guide surgical decision-making, individualise treatment intensity, plan discharge, and identify those nearing end of life.
Learning Objectives (from the lecture):
- Define frailty and its two conceptual models (phenotypic frailty vs. deficit accumulation)
- Know the epidemiology and consequences of frailty
- Understand the biological underpinnings of frailty
- Know how to screen for and assess frailty using validated tools
- Understand the clinical applications of frailty assessment (A&E, ward, surgical, EOL)
- Define sarcopenia, its pathophysiology, classification, and screening
- Recognise sarcopenia-related syndromes (sarcopenic obesity, sarcopenic dysphagia, osteosarcopenia)
- Manage frailty and sarcopenia with evidence-based interventions
How this fits into exams: Frailty and sarcopenia are tested in MCQ (tool selection, definitions), EMQ (matching assessment scales), SAQ (management of frail elderly, CGA), and mini-cases (pre-operative assessment, falls in frail elderly, EOL decisions). Past papers have explicitly tested assessment scales in the geriatric context [1].
1. Frailty — Definition and Core Concepts
"A biological syndrome of decreased reserve and resistance to stressors, resulting from cumulative decline across multiple physiologic systems, and causing vulnerability to adverse outcomes." — Fried et al 2001 [2]
Why this matters from first principles: Think of physiological reserve as a bank account. Young healthy adults have large reserves across multiple organ systems — cardiovascular, musculoskeletal, immune, neurological, endocrine. With ageing, each system loses some reserve. In most older adults, this decline is gradual and well-compensated. But in frailty, the decline is accelerated and multi-system, such that even a trivial insult (a cold, a fall, a new medication, a brief hospital stay) depletes the remaining reserve and triggers a disproportionate cascade of decompensation.
Frailty ≠ Disability ≠ Comorbidity
These three concepts overlap but are distinct. A patient with multiple comorbidities may not be frail if their reserves remain intact. A patient can be disabled from a stroke but not be frail. Frailty specifically refers to the vulnerability state from multi-system decline. The Fried phenotype was designed to be independent of disability and specific diseases. Exam traps often test this distinction.
1.2 Two Models of Frailty
| Feature | Phenotypic Frailty (Fried et al 2001) | Deficit Accumulation (Rockwood & Mitnitski 2007) |
|---|---|---|
| Core idea | Frailty is a specific clinical phenotype defined by 5 physical criteria | Frailty is a state arising from the accumulation of multiple deficits across all health domains |
| Criteria | 5 items (see below) | 21–70 deficits (diseases, disabilities, lab abnormalities, cognitive impairment, etc.) |
| Scoring | 0 = robust, 1–2 = pre-frail, 3–5 = frail | Frailty Index = deficits present / total deficits assessed |
| Threshold | ≥3 out of 5 = frail | FI > 0.25 often considered frail; FI > 0.70 threatens survival |
| Advantage | Simple, specific, widely validated | Captures the full spectrum of health; can use existing clinical data |
| Limitation | Narrow (physical only); misses cognitive/social domains | Requires more data; no single agreed-upon deficit list |
The 5 items of phenotypic frailty:
- Unintentional weight loss (> 4.5 kg or > 5% body weight in last year)
- Self-reported exhaustion (from CES-D depression scale)
- Weakness (low grip strength, measured by dynamometer)
- Slow walking speed (e.g. 15 feet timed walk)
- Low physical activity (measured by kcal/week)
Why these 5? They represent the final common pathway of multi-system decline: weight loss reflects catabolic state and malnutrition; exhaustion reflects energy dysregulation; weakness reflects sarcopenia; slow gait reflects neuromuscular and cardiovascular decline; low activity reflects the vicious cycle where inactivity accelerates further decline.
Deficits accumulation of multiple etiologies → Reduced redundancy → Increased vulnerability [2]
First principles: Biological systems have redundancy (backup capacity). As deficits accumulate — a bit of renal impairment here, mild cognitive decline there, some osteoporosis, some anaemia — the system loses redundancy. At some point, the loss of redundancy crosses a threshold where even small additional insults cause cascading failure.
The Frailty Index (FI) = (number of deficits present) / (total deficits assessed). At least 30 deficits should be assessed. An FI > 0.70 is virtually a ceiling — less than 1% of people in studies exceed this, suggesting it represents a level of deficit burden incompatible with survival [3].
Prevalence (from the lecture):
- US: 9.9% using Fried scale
- Asia-Pacific: 3.5–27%
- Hong Kong: 7.9% (Lee JS et al, JAMDA 2014)
- Frailty more common in older women [2]
From the NEJM review [3]: prevalence ranges from 11% in ages 50–59 to 51% in ages ≥90 across 62 countries. Higher in acute care hospitals, nursing homes, low/middle-income countries, and those with social vulnerability.
Why women? Longer life expectancy means more time to accumulate deficits; hormonal changes post-menopause accelerate bone and muscle loss; lower baseline muscle mass (sarcopenia threshold reached sooner).
Associated with adverse outcomes:
- Falls
- Disability
- Hospitalization
- Institutionalization
- Death
- Health care expenses ~US$4000 over 3 months for frail older adults (5× cost for non-frail adults) [2]
Why? Each adverse outcome feeds into the next in a vicious cycle: frailty → fall → hip fracture → hospitalisation → deconditioning → worsening frailty → institutionalisation → death.
The lecture lists 12 biological underpinnings — all are multifactorial and interconnected: [2]
| Mechanism | Explanation |
|---|---|
| Proinflammatory state (Walston 2002) | Chronic low-grade inflammation ("inflammaging") with elevated IL-6, CRP, TNF-α drives catabolism and sarcopenia |
| Sarcopenia (Ferrucci 2002) | Core driver — loss of muscle mass and strength → weakness, slow gait, falls |
| Anaemia (Chaves 2005) | Reduces oxygen delivery → fatigue, functional decline; often multifactorial in elderly |
| Relative androgen deficiency (low DHEAS) (Leng 2004) | Androgens are anabolic; decline contributes to muscle wasting |
| Decreased GH and IGF-1 (Chu LW 2001) | Growth hormone axis maintains muscle/bone; decline → sarcopenia and osteoporosis |
| Excess cortisol (Varadhan 2008) | Catabolic hormone; cortisol excess promotes protein breakdown, insulin resistance |
| Insulin resistance (Barzilay 2007) | Impairs glucose utilisation by muscle; promotes inflammation |
| Compromised immune function (Yao 2011) | Immunosenescence → susceptibility to infections → accelerated decline |
| Micronutrient deficiencies and oxidative stress (Semba 2007) | Vitamin C, E, carotenoid deficiency → oxidative damage to cells |
| Decreased 25(OH) vitamin D (Pabst 2015) | Vitamin D deficiency → muscle weakness, bone loss, falls |
| Chronic CMV infection (Wang 2010) | Drives T-cell clonal expansion → immune exhaustion |
| Dysregulation of autonomic nervous system (Varadhan 2009) | Impaired heart rate variability and baroreceptor function → orthostatic hypotension, falls |
Integration: These factors don't act in isolation. Inflammation drives sarcopenia, which causes inactivity, which worsens insulin resistance, which promotes more inflammation — a self-reinforcing cycle of decline. This is why single-target interventions (e.g. giving testosterone alone) generally fail, while multi-modal interventions (exercise + nutrition + CGA) succeed.
5. Clinical Frailty Assessment — Screening Tools
More than 70 screening tools exist — complicated! [2]
Screen all persons over age 70, and adults with multiple chronic illnesses or weight loss ≥5 kg over a year (Morley JE et al, JAMDA 2013) [2]
| Tool | Details | Time | Notes |
|---|---|---|---|
| Timed Up and Go (TUG) | Single-item; > 15 sec associated with post-op complications and 1-year mortality | ~1 min | Simple bedside test |
| Fried Frailty Phenotype | 5 criteria (weight loss, exhaustion, weakness, slow gait, low activity); 0 = fit, 1–2 = pre-frail, ≥3 = frail | ~10 min | Research gold standard |
| Frailty Index (FI) | Deficit accumulation model; 21–70 deficits; FI-CGA when coupled with CGA | Variable | Most granular |
| "FRAIL" Scale (Morley) | Fatigue, Resistance, Ambulation, Illnesses, Loss of weight; 0 = robust, 1–2 = pre-frail, 3–5 = frail | ~5 min | Quick questionnaire |
| Clinical Frailty Scale (CFS, Rockwood) | 9-point visual/descriptive scale from 1 (very fit) to 9 (terminally ill) | ~5 min | Most widely used clinically; used during COVID-19 triage |
| PRISMA 7 | 7 yes/no questions | ~3 min | Community screening |
| Edmonton Frail Scale (EFS) | 11 domains including cognition, mood, function, social support | ~5 min | Includes clock-drawing test |
| Tilburg Frailty Indicator (TFI) | Self-report covering physical, psychological, social domains | ~10 min | Multidimensional |
| SARC-F | Sarcopenia-specific screen; 5 items (Strength, Assistance walking, Rising from chair, Climbing stairs, Falls) | ~2 min | High specificity but low sensitivity |
| Score | Category | Description |
|---|---|---|
| 1 | Very fit | Robust, active, energetic, exercise regularly |
| 2 | Well | No active disease, less fit than category 1, occasionally active |
| 3 | Managing well | Medical problems well-controlled, routine walking only |
| 4 | Vulnerable | Not dependent but "slowed up", tired during the day |
| 5 | Mildly frail | Need help with IADLs (finances, transport, heavy housework, medications) |
| 6 | Moderately frail | Need help with all outside activities + problems with stairs/bathing; may need help dressing |
| 7 | Severely frail | Completely dependent for personal care (physical or cognitive); stable, not at high risk of dying within ~6 months |
| 8 | Very severely frail | Completely dependent, approaching end of life; could not recover from minor illness |
| 9 | Terminally ill | Life expectancy < 6 months, not otherwise evidently frail |
For dementia: the degree of frailty corresponds to the degree of dementia [4]
CFS Scoring in Dementia
Mild dementia (forgetting details of recent events, repeating stories, social withdrawal) ≈ CFS 5. Moderate dementia ≈ CFS 6. Severe dementia with complete dependence ≈ CFS 7. This is important for exam scenarios asking about frailty in cognitively impaired patients.
An electronic Frailty Index (eFI) has been developed by HAHO and will be available soon in all HA hospitals [2]
This uses routinely collected clinical data from electronic health records to automatically calculate a Frailty Index, enabling population-level screening without additional clinical assessment time.
6. Clinical Applications of Frailty Assessment
Facilitates treatment plan and disposal:
- Hospitalisation vs. discharge from A&E
- Acute hospital vs. step-down geriatric hospitals
- Discharge with community-based care: CGAT, CVMO, ECEOL, GDH, ICDS (ICM CM or IDSP HST), PSCC, CNS, VMP, MDOST, DSCC [2]
Why this matters: Frailty assessment at the "front door" of the hospital (A&E) allows triaging of older adults into the most appropriate care pathway. A fit 80-year-old with a UTI may safely go home with antibiotics. A frail 80-year-old with the same UTI may need admission because the infection could trigger delirium, falls, and functional decline.
Key ward-based interventions for frail elderly: [2]
- Prevention of delirium
- Pressure sore prevention
- Fall prevention
- Rehabilitation
- Nutrition support
- Avoiding polypharmacy
- Early discharge planning
- Appropriate placement
Why each matters:
- Delirium prevention: Frail patients have minimal cognitive reserve; medications, infections, constipation, or unfamiliar environments easily tip them into delirium. Non-pharmacological multicomponent strategies (orientation, sleep hygiene, hydration, early mobilisation, minimising tethers) are the evidence base.
- Pressure sore prevention: Immobility + malnutrition + thin skin = pressure injury. Turning schedules, pressure-relieving mattresses, nutritional optimisation.
- Fall prevention: Multifactorial assessment (medications, vision, footwear, environment, postural hypotension, balance training).
- Nutrition support: Malnutrition accelerates sarcopenia; dietitian involvement, oral nutritional supplements, protein intake optimisation.
- Avoiding polypharmacy: Every additional medication increases the risk of adverse drug events, drug-drug interactions, and non-adherence. Use STOPP/START criteria [5].
- Early DC planning: Prolonged hospitalisation causes deconditioning ("hospital-acquired disability"). Aim for early, safe discharge.
- Appropriate placement: Not everyone can go home — assess need for RCHE, community support services.
Frailty is independently associated with mortality [2]
- The more frail → the higher the 3-year mortality
- Worsening frailty status in previous 2 years predicts higher mortality in the next 2 years
- Chinese large-scale study: 3-year mortality 14.4% in least frail → 73% in most frail
- Local HK study in RCHE: advanced dementia cases — mortality 34% in one year (Luk JKH et al, HK Med J 2013)
Why this matters: Frailty trajectories help identify patients approaching end of life. Unlike cancer, where the trajectory is a relatively predictable decline, frailty-related dying follows a pattern of stepwise decline with each acute illness causing a further drop in function, with incomplete recovery each time. Recognising this trajectory is essential for initiating advance care planning discussions.
From the NEJM review [3]: End-stage frailty = Fried phenotype 5/5, or FI approaching 0.70, or CFS 8–9 (complete dependence). Management should focus on comfort and dignity through palliative care and hospice.
Frailty predicts poorer surgical outcomes:
- Surgical complications
- Longer length of stay (LOS)
- Discharge to institution
- Mortality [2]
Pre-operative frailty assessment enhances:
- Risk management pre-op: medication review, nutritional augmentation, PT/OT (prehabilitation)
- Post-op management: pressure sore prevention, delirium prevention, attention to hydration/nutrition, early mobilisation [2]
Why prehabilitation works: If you can increase a patient's physiological reserve before the surgical stressor, they are more likely to tolerate the surgery and recover. Even 2–4 weeks of progressive resistance exercise and nutritional optimisation pre-operatively can improve outcomes.
This framework from the NEJM review [3] is a comprehensive approach to tailoring care based on frailty level:
| Domain | Fit (CFS 1–3, FI < 0.10) | Pre-frail (CFS 4, FI 0.10– < 0.20) | Frail (CFS 5–7, FI 0.20– < 0.55) | End-stage Frailty (CFS 8–9, FI ≥0.55) |
|---|---|---|---|---|
| Goal | Increase physiological reserve | Increase physiological reserve | Preserve reserve, prevent stressors | Provide comfort |
| Lifestyle | Exercise, high-quality diet, social engagement | Exercise, protein-rich diet, social engagement | Less intense exercise; protein-rich diet; social engagement | Activity/diet as tolerated |
| Disease Mx | Apply standard guidelines | Apply standard guidelines | Consider trade-off between disease burden and treatment burden; de-escalate | De-escalate treatments |
| Preventive care | Vaccination, cancer screening | Vaccination, cancer screening | Vaccination; individualise cancer screening (time to benefit vs. remaining life expectancy) | Vaccination; stop cancer screening |
| Interventions | Healthy lifestyle, chronic disease management | CGA if suspected frailty; identify treatable causes | CGA; exercise + nutrition; address depression, anaemia, hypothyroidism, B12 deficiency, polypharmacy | Palliative care, hospice |
| Social support | Minimal | Emerging needs | Essential for adherence to care plans, ADL assistance | Family support, end-of-life care |
High-Yield Treatable Causes of Frailty
When frailty is identified, look for potentially reversible precipitants: depression, anaemia, hypotension, hypothyroidism, vitamin B12 deficiency, unstable medical conditions, adverse drug events [3]. These are high-yield exam targets — always think about what you can fix.
8. Sarcopenia
"A syndrome characterised by progressive and generalised loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life and high mortality." — EWGSOP, supported by AWGS [2]
Two milestones:
- 2010: Introduction of muscle function into the concept (previously defined by mass alone)
- 2016: Recognition as an independent condition with ICD-10 code (M62.84) [2]
Muscle mass:
- After age 30: ↓ ~1%/year
- After age 70: accelerates to ↓ ~1.5%/year
Muscle strength:
- Ages 50–60: ↓ ~1–1.5%/year
- After age 60: ↓ ~3%/year [2]
Why strength declines faster than mass: Because strength depends not only on muscle quantity but also on neuromuscular function (motor unit recruitment, nerve conduction), muscle quality (fat infiltration), and coordination. These decline in parallel, creating a multiplicative effect.
Three key pathological changes: [2]
- Imbalance between muscle protein anabolism and catabolism → overall loss of skeletal muscle
- Reduced type II (fast-twitch) fibres with transition to type I (slow-twitch) fibres
- Intramuscular and intermuscular fat infiltration (myosteatosis)
First principles:
- Type II fibres are fast-twitch, responsible for rapid, powerful contractions (e.g. getting up from a chair, catching yourself from a fall). These are preferentially lost in ageing, which is why older adults lose power before endurance.
- Myosteatosis (fatty infiltration) reduces the contractile tissue per unit of muscle cross-section, so even if the limb looks the same size on imaging, the muscle is weaker.
Primary sarcopenia: Aging itself is the predominant cause
Secondary sarcopenia: Due to:
- Inactivity (bed rest, sedentary lifestyle, deconditioning, zero-gravity)
- Malnutrition (inadequate dietary intake)
- Disease (advanced organ failure, cancer, inflammatory diseases) [2]
Three domains: [2]
| Domain | Measure | Cut-off (Male) | Cut-off (Female) |
|---|---|---|---|
| Muscle strength | Handgrip strength | < 28 kg | < 18 kg |
| Physical performance | 6-m walk speed | < 1.0 m/s | < 1.0 m/s |
| SPPB score | ≤9 | ≤9 | |
| 5-time chair stand test | ≥12 seconds | ≥12 seconds | |
| Muscle mass (Skeletal Mass Index) | DXA | < 7.0 kg/m² | < 5.4 kg/m² |
| Bioimpedance (BIA) | < 7.0 kg/m² | < 5.7 kg/m² |
Handgrip strength measurement: Take 6 tests (3 right hand, 3 left hand), take the highest value [2]
Calf circumference: Male > 34 cm, Female > 33 cm (used as a simple screening surrogate for muscle mass) [2]
The detection pathway follows a staged approach:
- Screen with SARC-F (or SARC-F + calf circumference) or by case-finding
- Assess muscle strength (grip strength) or physical performance (chair stand test or gait speed)
- If abnormal → "possible sarcopenia" — sufficient to start interventions in primary care
- Confirm with muscle mass measurement (DXA or BIA) → confirmed sarcopenia
- If low muscle mass + low strength + low performance → "severe sarcopenia"
Universal screening is not evidence-based. A case-finding approach is advocated: [2]
Screen in patients with:
- Falls
- Slowness and weakness
- Decreased walking mobility and walking speed
- Weight loss
- Decreased ADL
- Self-reported muscle wasting
- Admission to hospital / RCHEs
High specificity but low sensitivity [2]
The SARC-F questionnaire asks about:
- Strength (difficulty lifting/carrying 10 lbs?)
- Assistance in walking (difficulty walking across a room?)
- Rise from a chair (difficulty transferring from chair/bed?)
- Climb stairs (difficulty climbing 10 stairs?)
- Falls (how many falls in the past year?)
Score ≥4 suggests sarcopenia. Its low sensitivity means it misses early/mild cases, so negative SARC-F does not rule out sarcopenia — clinical judgement and case-finding remain important.
Prevalence (age > 65): [2]
- Australia (EWGSOP): 6.4% men, 9.3% women
- China (AWGS): 26.2% men, 33.6% women
- Hong Kong (EWGSOP): 9%
8.10 Sarcopenia-Related Syndromes
Co-presence of sarcopenia and obesity with excessive fat mass in the presence of reduced muscle mass. Both are associated with metabolic disorders, morbidity, and mortality. [2]
Why it's dangerous: Obesity alone increases metabolic risk. Sarcopenia alone increases fall/fracture/disability risk. Together, they create a synergistic effect — the excess fat drives inflammation which accelerates muscle loss, while reduced muscle mass impairs metabolic health further. These patients may look "normal weight" or even overweight but have dangerously low muscle mass hidden under fat.
Normal age-related change in swallowing = "presbyphagia." Swallowing muscles have moderate-to-high percentage of type II fibres because normal swallowing requires rapid contraction. Sarcopenia preferentially depletes type II fibres → impaired swallowing. [2]
Clinical significance: Sarcopenic dysphagia → aspiration risk → aspiration pneumonia → further decline. This is distinct from neurogenic dysphagia (stroke, Parkinson's) and must be considered in malnourished frail elderly.
Coexistence of osteoporosis and sarcopenia. This group, especially with concurrent frailty, has higher chance of falls AND fracture than either condition alone. [2]
Why they co-occur: Muscle and bone are mechanically and biochemically linked. Mechanical loading from muscle contraction stimulates bone formation (Wolff's law). When muscle mass and function decline, bone loading decreases → accelerated bone loss. Shared hormonal mediators (vitamin D, GH/IGF-1, sex steroids) decline simultaneously.
9. Management of Frailty and Sarcopenia
Frailty overlaps with sarcopenia — many management strategies are shared between the two. [2]
Resistance exercise improves: [2]
- Muscle strength
- Muscle mass
- Balance
Why resistance over aerobic: While aerobic exercise has cardiovascular benefits, resistance (strength) training specifically stimulates muscle protein synthesis and counteracts the type II fibre loss that characterises sarcopenia. Progressive resistance training 2–3 times/week is the cornerstone intervention.
From the NEJM review [3]: Exercise is the single most effective intervention for frailty. Multicomponent exercise (resistance + balance + flexibility) is ideal. Even in very frail patients, adapted exercise programs show benefit, though the intensity may need to be reduced.
Better when coupled with resistance exercise (Tieland et al) ESCEO recommends protein intake of 1.0–1.2 g/kg body weight/day [2]
Why 1.0–1.2 g/kg? The standard adult RDA of 0.8 g/kg/day is insufficient for older adults because of anabolic resistance — ageing muscle requires a higher protein stimulus to achieve the same rate of protein synthesis. Distributing protein evenly across meals (rather than loading at dinner) optimises muscle protein synthesis.
β-hydroxy β-methylbutyrate (HMB): May preserve or increase lean muscle mass and strength in sarcopenic older adults; more studies needed [2]
HMB is a metabolite of leucine that inhibits muscle protein breakdown. It's available as a supplement but the evidence is still emerging.
ESCEO recommends: [2]
- Vitamin D 800 IU/day to maintain 25(OH)D > 50 nmol/L
- Calcium 1000 mg/day
- Regular exercise 3–5 times/week
- These prevent osteosarcopenia
The following have been tried but LACK sufficient evidence: [2] Combined estrogen-progesterone, DHEA, Growth Hormone, GH-releasing hormone, Testosterone, IGF-1, Pioglitazone, Omega-3 PUFA, ACEI
Selective Androgen Receptor Modulators (SARMs): Of particular interest because of tissue selectivity — hoped to achieve gains in muscle without dose-limiting side effects of androgens. Still in clinical development. [2]
Why single-target pharmacotherapy fails: Frailty and sarcopenia are multi-system problems. Giving testosterone might build some muscle but doesn't address inflammation, nutritional deficits, inactivity, or neurodegeneration. This is why multi-modal interventions (exercise + nutrition + CGA) consistently outperform single-target drugs.
From the NEJM review [3]: CGA is itself an intervention. It involves systematic multidimensional assessment of medical, functional, cognitive, psychological, social, and environmental domains with the creation of an integrated care plan. CGA-based care has been shown to reduce frailty, institutional admission, and mortality in hospitalised older adults.
| Intervention | Evidence Level | Key Points |
|---|---|---|
| Resistance/multicomponent exercise | Strong | Cornerstone; improves strength, mass, balance, reduces falls |
| Protein supplementation | Moderate | 1.0–1.2 g/kg/day; best combined with exercise |
| Vitamin D (800 IU/day) | Moderate | Maintains muscle function, prevents falls/fracture when combined with Ca |
| CGA | Strong | Multi-domain assessment with integrated care plan |
| Medication review (deprescribing) | Moderate-Strong | Reduce polypharmacy, avoid PIMs (STOPP/START, Beers) |
| HMB | Emerging | May preserve lean mass; more evidence needed |
| SARMs | Experimental | In clinical development; tissue-selective androgens |
| Hormone therapies (GH, testosterone, DHEA) | Insufficient | Not recommended as standard treatment |
11. Exam Intelligence
- 2018 EMQ [1]: "USE OF ASSESSMENT SCALES IN GERIATRIC MEDICINE" — tested Barthel Index, MoCA, MUST, FRAIL score, handgrip dynamometer. Key learning: Know which tool measures what. Frailty = FRAIL score or CFS. Grip strength = handgrip dynamometer (for sarcopenia). Nutrition = MUST. Cognition = MoCA. Function (ADL) = Barthel. Function (IADL) = Lawton's.
- Frailty definition questions: Expect MCQs asking you to identify the 5 Fried criteria or differentiate frailty from disability/comorbidity.
- Sarcopenia diagnostic cut-offs: Grip strength thresholds (< 28 kg male, < 18 kg female) and AWGS criteria are testable.
- Management priorities: "What is the most important intervention for sarcopenia?" → Resistance exercise.
| Trap | Correct Answer |
|---|---|
| "Frailty = old age" | No — frailty is a specific clinical syndrome, not synonymous with ageing |
| "Frailty = disability" | No — distinct concepts; frailty is vulnerability, disability is functional limitation |
| "BMI can diagnose sarcopenia" | No — sarcopenic obesity means normal/high BMI but low muscle mass; need DXA/BIA |
| "SARC-F is a good screening tool because of high sensitivity" | No — SARC-F has high specificity but LOW sensitivity |
| "Testosterone is first-line for sarcopenia" | No — resistance exercise is first-line; testosterone lacks evidence and has side effects |
| "Universal sarcopenia screening is recommended" | No — case-finding approach is advocated; universal screening is NOT evidence-based |
| "Frail patients should not receive any treatment/surgery" | No — frailty should not be used to withhold effective treatment; it guides shared decision-making |
"List 5 components of the Fried frailty phenotype" — write all 5 with brief description:
- Unintentional weight loss
- Self-reported exhaustion
- Weakness (grip strength)
- Slow walking speed
- Low physical activity
"Describe 4 ward-based interventions for a frail elderly patient admitted to hospital" — pick from the 8 listed on the lecture slide and explain WHY each is important.
"Outline the management of sarcopenia" — structure as:
- Exercise (resistance training — strongest evidence)
- Nutrition (protein 1.0–1.2 g/kg/day, coupled with exercise)
- Vitamin D + Calcium (800 IU + 1000 mg)
- Address underlying causes (secondary sarcopenia: treat disease, improve activity)
- Consider emerging agents (HMB, SARMs — mention but note lack of strong evidence)
-
Define frailty. List the 5 criteria of the Fried phenotypic frailty model.
- Markscheme: Definition (biological syndrome of decreased reserve → vulnerability to adverse outcomes). Five criteria: unintentional weight loss, self-reported exhaustion, weakness (grip strength), slow walking speed, low physical activity. ≥3 = frail, 1–2 = pre-frail, 0 = robust.
-
What are the consequences of frailty in older adults?
- Markscheme: Falls, disability, hospitalisation, institutionalisation, death. Increased healthcare costs (~5× non-frail).
-
An 85-year-old lady presents to A&E with a fall. Describe how frailty assessment would guide her management.
- Markscheme: Use CFS or FRAIL scale to assess frailty level. Guides disposition (home vs. admission vs. step-down). If frail: full CGA, address falls risk factors, delirium prevention, nutrition, medication review, early DC planning, appropriate placement.
-
What is sarcopenia? List the AWGS diagnostic criteria including cut-off values.
- Markscheme: Progressive loss of skeletal muscle mass and strength → physical disability, poor QoL, mortality. Grip strength < 28 kg (M)/ < 18 kg (F); gait speed < 1.0 m/s or chair stand ≥12s; muscle mass by DXA < 7.0 (M)/ < 5.4 (F) kg/m².
-
What is the first-line treatment for sarcopenia?
- Markscheme: Resistance exercise (strong recommendation). Improves muscle strength, mass, and balance. Best combined with protein supplementation (1.0–1.2 g/kg/day) and vitamin D (800 IU/day).
-
Describe the pathophysiology of sarcopenia at the muscle fibre level.
- Markscheme: Imbalance between anabolism and catabolism → net muscle loss. Preferential loss of type II (fast-twitch) fibres with transition to type I (slow-twitch). Intramuscular fat infiltration (myosteatosis).
-
Compare and contrast frailty, disability, and comorbidity.
- Markscheme: Frailty = vulnerability from multi-system decline (may exist without disability). Disability = difficulty/inability performing specific activities (may exist without frailty, e.g. amputation). Comorbidity = coexistence of ≥2 diseases (may exist without frailty if reserve intact). The three overlap but are distinct constructs.
-
What is osteosarcopenia and why is it clinically important?
- Markscheme: Coexistence of osteoporosis and sarcopenia. Higher risk of falls (from sarcopenia) AND fracture (from osteoporosis) than either alone. Muscle and bone share mechanical and hormonal links. Management: exercise, vitamin D + calcium, protein.
Active Recall - Frailty and Sarcopenia in Older People
High Yield Summary
Frailty is a state of diminished physiological reserve causing vulnerability to adverse outcomes — distinct from ageing, disability, and comorbidity. Two models: Fried phenotype (5 physical criteria: weight loss, exhaustion, weakness, slow gait, low activity; ≥3 = frail) and deficit accumulation (Frailty Index: deficits/total assessed; FI > 0.70 ≈ survival limit). Prevalence ~8% in HK elderly, higher in women. Consequences: falls, disability, hospitalisation, institutionalisation, death, 5× cost. Screen all > 70y or with chronic illness/weight loss. Key tools: CFS (9-point), FRAIL scale, TUG, Fried phenotype, FI. Sarcopenia = progressive loss of muscle mass + strength; AWGS criteria: grip < 28/18 kg, gait < 1.0 m/s or chair stand ≥ 12s, DXA < 7.0/5.4 kg/m². Pathology: type II fibre loss, myosteatosis. Related syndromes: sarcopenic obesity, sarcopenic dysphagia, osteosarcopenia. Management of both: resistance exercise (strongest evidence), protein 1.0–1.2 g/kg/day, vitamin D 800 IU/day + Ca 1000 mg/day, CGA, medication review, address reversible causes (depression, anaemia, hypothyroidism, B12 deficiency, polypharmacy). Ward care: delirium/fall/pressure sore prevention, nutrition, early DC planning. Pre-op: prehabilitation. End-stage frailty: palliative care.
[1] Past papers: 2018 Fourth Summative MCQ (Section B, Q.1–Q.3) [2] Lecture slides: GC 054. Frailty in the older people.pdf (all pages) [3] Supporting source: Frailty in Older Adults - Kim DH 2024 (NEJM).pdf [4] AOS material: AOS - Geriatrics.pdf (Clinical Frailty Scale description, p.30) [5] Lecture slides: GC 079. Prescribing in older people.pdf (STOPP/START criteria)
GC053 Fingers Turn White And Blue
Raynaud phenomenon is episodic vasospasm of the digital arteries causing sequential color changes of the fingers—white (ischemia), blue (cyanosis), and red (reperfusion)—typically triggered by cold exposure or emotional stress.
GC056 Generalized Muscle Weakness
Generalized muscle weakness is a diffuse reduction in muscle strength affecting multiple muscle groups, resulting from neurological, muscular, metabolic, or systemic disorders that impair the ability to generate normal voluntary force.